Browsing by Author Thurlimann, B.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 18 of 18
Issue DateTitleAuthor(s)Citation
2010Adjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancerCoates, Alan; Cole, Bernard; Crivellari, Diana; Gelber, Richard; Gelber, Shari; Goldhirsch, A; Holmberg, Stig B.; Paridaens, Robert; Price, Karen N.; Thurlimann, B.; School of Public Health: Public HealthAdjuvant! Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer, Breast Cancer Research and Treatment, vol.123, 1,pp 303-310
2016Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the international breast cancer study group trials I to VCoates, Alan; Castiglione-Gertsch, Monica; Colleoni, Marco; Forbes, John F.; Gelber, Richard; Gianni, Lorenzo; Goldhirsch, Aron; Karlsson, Per; Price, Karen; Sun, Zhuoxin; Thurlimann, B.; School of Public Health: Public HealthAnnual hazard rates of recurrence for breast cancer during 24 years of follow-up: Results from the international breast cancer study group trials I to V, Journal of Clinical Oncology, vol.34, 9, 2016,pp 927-935
2011Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-upCoates, Alan; Ejlertsen, Bent; Forbes, John F.; Gelber, Richard; Giobbie-Hurder, Anita; Goldhirsch, Aron; Lang, Istvan; Mauriac, Louis; Neven, Patrick; Price, Karen N.; Rabaglio, Manuela; Regan, Meredith M.; Smith, Ian (Prof); Thurlimann, B.; Wardley, Andrew; School of Public Health: Public HealthAssessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up, Lancet Oncology, vol.12, 12, 2011,pp 1101-1108
2014Bone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequencesCoates, Alan; Campone, Mario; Debled, M.; DeCensi, Andrea; et al, Various; Guerrieri-Gonzaga, Aliana; McIntosh, Christina; Monnier, Alain; Schönenberger, Astrid; Sun, Zhuoxin; Thurlimann, B.; Tondini, Carlo; School of Public Health: Public HealthBone mineral density and circulating biomarkers in the BIG 1-98 trial comparing adjuvant letrozole, tamoxifen and their sequences, Breast Cancer Research and Treatment, vol.144, 2, 2014,pp 321-329
2011Cognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trialCoates, Alan; Aldridge, Julie; Bernhard, Jurg; Cardoso, Fatima; Gelber, RD; Goldhirsch, Aron (Prof); Harvey, V; Pagani, O.; Phillips, Kelly-Anne; Price, K N; Ribi, Karin; Sun, Zhuoxin; Thompson, Alastair; Thurlimann, B.; School of Public Health: Public HealthCognitive function in postmenopausal breast cancer patients one year after completing adjuvant endocrine therapy with letrozole and/or tamoxifen in the BIG 1-98 trial, Breast Cancer Research and Treatment, vol.126, 1, 2011,pp 221-226
2010Cognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trialCoates, Alan; Bernhard, Jurg; Cardoso, Fatima; Gelber, Richard D. (Prof); Goldhirsch, A; Harvey, V; Pagani, O.; Phillips, Kelly-Anne; Price, Karen; Ribi, Karen; Stephens, Alisa; Sun, Zhuoxin; Thompson, Alastair; Thurlimann, B.; School of Public Health: Public HealthCognitive function in postmenopausal women receiving adjuvant letrozole or tamoxifen for breast cancer in the BIG 1-98 randomized trial, The Breast, vol.19, 5,pp 388-395
2003Comments on the St. Gallen Consensus 2003 on the primary therapy of early breast cancerCoates, Alan; Gelber, Richard D. (Prof); Goldhirsch, Aron (Prof); Senn, H.-J.; Thurlimann, B.; Wood, W. C.; School of Public Health: Public HealthComments on the St. Gallen Consensus 2003 on the primary therapy of early breast cancer, Breast, vol.12,(N/A),2003,pp 569-582
2015CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trialCoates, Alan; Abramovitz, Mark; Biasi, Maria Olivia; Bouzyk, Mark; Dell’Orto, Patrizia; et al, Various; Gray, Kathryn P; Kammler, Roswitha; Leyland-Jones, Brian; Long, Bradley; Thurlimann, B.; Young, Brandon; School of Public Health: Public HealthCYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial, Breast Cancer Research and Treatment, vol.151, 2, 2015,pp 373-384
2006First-select the target: better choice of adjuvant treatments for breast cancer patients.Coates, Alan; Gelber, Richard D. (Prof); Glick, J. H.; Goldhirsch, Aron (Prof); Senn, Hans-Jorg; Thurlimann, B.; School of Public Health: Public HealthFirst-select the target: better choice of adjuvant treatments for breast cancer patients., Annals of Oncology 2005, vol.17,(12),2006,pp 1772-1776
2009Is adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93.Coates, Alan; Castiglione-Gertsch, Monica; Collins, John; Crivellari, Diana; et al, various; Gelber, Richard D. (Prof); Gelber, Shari; Holmberg, Stig B.; Lindtner, Jurij; Pagani, O.; Price, Karen N.; Simoncini, Edda; Thurlimann, B.; School of Public Health: Public HealthIs adjuvant chemotherapy of benefit for postmenopausal women who receive endocrine treatment for highly endocrine-responsive, node-positive breast cancer? International Breast Cancer Study Group Trials VII and 12-93., Breast Cancer Research and Treatment, vol.116, 3,pp 491-500
2003Meeting highlights: updated international expert consensus on the primary therapy of early breast cancerCoates, Alan; Gelber, Richard D. (Prof); Goldhirch, Aron; Senn, Hans-Jorg; Thurlimann, B.; Wood, W. C.; School of Public Health: Public HealthMeeting highlights: updated international expert consensus on the primary therapy of early breast cancer, Journal of Clinical Oncology, vol.21,(17),2003,pp 3357-3365
2015Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trialCoates, Alan; Bibeau, Frederic; Ejlertsen, Bent; et al, Various; Giobbie-Hurder, Anita; Gusterson, Barry A; Lelkaitis, Gierdrius; MacGrogan, G.; Mallon, Elizabeth; Munzone, Elisabetta; Thurlimann, B.; Viale, Giuseppe; School of Public Health: Public HealthOutcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial, Annals of Oncology, vol.26, 12, 2015,pp 2442-2449
2013Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Coates, Alan; Gelber, RD; Goldhirsch, A; Piccart-Gebhart, Martine J (Prof); Senn, H.-J.; Thurlimann, B.; Winer, EP; School of Public Health: Public HealthPersonalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013, Annals of Oncology, vol.24, 9, 2013,pp 2206-2223
2003Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VIICoates, Alan; Bonetti, M; Castiglione-Gertsch, Monica; et, al; Fey, Martin F.; Gelber, Richard D. (Prof); Goldhirsch, A; Holmberg, Stig B.; Lindtner, Jurij; Thurlimann, B.; Wallgren, A; School of Public Health: Public HealthRisk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII, Journal of Clinical Oncology, vol.21,(7),2003,pp 1205-1213
2011Strategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011Coates, Alan; Gelber, Richard D. (Prof); Goldhirsch, Aron; Senn, H.-J.; Thurlimann, B.; Wood, W. C.; School of Public Health: Public HealthStrategies for subtypes-dealing with the diversity of breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011, Annals of Oncology, vol.22, 8, 2011,pp 1736-1747
2015Tailoring therapies - improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015Coates, Alan; Gelber, Richard D; Gnant, Michael; Goldhirsch, A; Piccart-Gebhart, Martine J (Prof); Senn, H-J; Thurlimann, B.; Winer, EP; School of Public Health: Public HealthTailoring therapies - improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015, Annals of Oncology, vol.26, 8, 2015,pp 1533-1546
2009Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009.Coates, Alan; Gelber, Richard D. (Prof); Goldhirsch, A.; Ingle, J.; Senn, H.-J.; Thurlimann, B.; School of Public Health: Public HealthThresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009., Annals of Oncology, vol.20, 8,pp 1319-1329
2011Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial.Coates, Alan; Colleoni, Marco; Dell'Orto, Patrizia; Forbes, John F.; Gelber, Richard D. (Prof); Goldhirsch, A.; Gusterson,, B; Lang, Istvan; MacGrogan, G; Maiorano, Eugenio; Mastropasqua, M; Mauriac, L; Mouridsen, Henning; Paridaens, R.J.; Price, Karen; Rasmussen, B; Regan, Meredith M.; Thurlimann, B.; Viale, Giuseppe; School of Public Health: Public HealthWhich patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial., Annals of Oncology, vol.22, 10, 2011,pp 2201-7